Patient Preferences Drive Value in Direct-to-Patient Programs

Check out our newly released research report on DTP and how to best set-up a direct-to-patient program that drives access, affordability and adherence The data is very clear: DTP has the potential to bridge the awareness-to-access gap, drive improved affordable options and create an intuitive digital experience Read more here: https://lnkd.in/gAmFQzu5 Mirah Gocher Haley Nagel Chris Sweitzer Russell Salvatore Sahil Naik

Patients increasingly expect medication access to work like the rest of their digital lives. A new survey of 1,000+ U.S. patients from PHIL, Inc. explores what they want from direct-to-patient programs.

Convenience may be more powerful than technology in shaping how healthcare gets delivered. Direct-to-patient care models gained early traction with lifestyle medications, where clinical risk was relatively low and the case for accessibility was straightforward. Recent expansion into branded, chronic, and disease-modifying therapies has changed the conversation. Monitoring requirements, therapeutic index, continuity of care, and clinical oversight are now competing with access and consumer experience in ways they weren't before. Join me and Timothy Aungst, PharmD. at the Total Pharmacy Solutions Summit Spring 2026 to discuss this shift and what it may mean for practice. Excited for the chance to think through these questions with colleagues working on the future of practice. Live virtual event, March 14 | 9:00 AM to 3:00 PM EDT (our session begins around 1:00 PM ET). Registration is free: https://bit.ly/4kMDNU8 Thanks to Drug Topics for the opportunity and to SMIT PATEL💊📲 for expert feedback and insight on the topic. #pharmacy #healthtech #directtopatient #innovation

Healthcare platforms are moving beyond product delivery. From 30-minute delivery for urgent OTC medicines to integrating diagnostics, consultations and wellness solutions, digital pharmacies are expanding how care is delivered. Prateek Verma, Founding Team Member and Leadership Team at Tata 1mg, in conversation with Praful Akali, Founder and MD, Medulla Communications, discusses how the focus is shifting from selling medicines to solving health needs. Click on the link below to watch the full conversation: https://lnkd.in/dcPTqPqp #ConsumerHealthcare #OTC #DigitalHealth #PatientCentricCare #HealthcareInnovation

𝗣𝗹𝗮𝘆𝟰𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 #𝟭 Every day, millions of patients pick up a device. An inhaler. An insulin pen. An auto-injector. They use it. They finish it. And then, for most pharma companies, the story ends there. Not because they don't care. Because they 𝗵𝗮𝘃𝗲 𝗻𝗼 𝘄𝗮𝘆 𝘁𝗼 𝘀𝗲𝗲 what happens next. That blind spot has a name: 𝗦𝗰𝗼𝗽𝗲 𝟯, 𝗖𝗮𝘁𝗲𝗴𝗼𝗿𝗶𝗲𝘀 𝟭𝟭 𝗮𝗻𝗱 𝟭𝟮.  Use of sold products. End-of-life treatment. Healthcare represents 𝗿𝗼𝘂𝗴𝗵𝗹𝘆 𝟰.𝟰% 𝗼𝗳 𝗴𝗹𝗼𝗯𝗮𝗹 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀, and most of it sits in these categories.  And most of it is estimated from models, spend data, and supplier surveys, not from what actually happens in the real world. The infrastructure to know the truth already exists.  Pharmacies, patient support programs, distribution networks. Because the biggest missing dataset in 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝘀 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿. That's the missing piece, not more models, not better spreadsheets. 𝗔 𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗵𝗮𝘁 𝘀𝗲𝗲𝘀 𝘁𝗵𝗲 𝗺𝗼𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗿𝗲𝗰𝗼𝗿𝗱𝘀 𝗶𝘁. → Play4Health Insight #1 of 10 : https://lnkd.in/d7Yc4C2R

A question for 𝗽𝗵𝗮𝗿𝗺𝗮 𝗘𝗦𝗚 𝗹𝗲𝗮𝗱𝗲𝗿𝘀, 𝗣𝗦𝗣 𝘁𝗲𝗮𝗺𝘀, 𝗮𝗻𝗱 𝗖𝗙𝗢𝘀. What percentage of your 𝗦𝗰𝗼𝗽𝗲 𝟯 𝗖𝗮𝘁𝗲𝗴𝗼𝗿𝘆 𝟭𝟮 𝗱𝗮𝘁𝗮 𝗶𝘀 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝘃𝗲𝗿𝗶𝗳𝗶𝗲𝗱? Not modeled, estimated from spend or based on industry averages. But linked to a 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗲𝗻𝘁 : a patient finishing a device, a device returned at a pharmacy, a verified end-of-life action. If the answer is close to zero, you’re not alone. Most of the sector is in the same situation. But as Scope 3 moves deeper into financial disclosure, audit scrutiny, and CSRD / IFRS reporting, that gap will become harder to justify. Curious how different companies are thinking about this.

"I am a huge proponent for precision medicine." Join us this week with Chloe Bright, Founder & Lead Consultant of Acumen Consultants, Inc. shares her expertise on innovative pharmacy solutions, including niche PBMs, pharmacogenomics, and future industry needs. Discover how these strategies can lead to significant cost savings and improved healthcare outcomes for employers and members. "Sending shockwaves through what those traditional cost containment pharmacy tools are." Chloe shares some that are on top of her list! US-RX Care EmpiRx Health DisclosedRx WellLife Network "In addition to the flexibility, they have a lot of technology in place for their members to have a better experience." Key Topics 💊 Niche PBMs and their advantages 🧬 Role of pharmacogenomics in cost savings 🚀 Emerging pharmacy technologies and solutions ⚠️ Industry challenges and future needs Join us for a quick 9 minutes to learn a lot about Revolutionizing Pharma benefits on Bending The Trend ⤵ https://lnkd.in/gyguHRgC

Excited to be featured on the Bending The Trend podcast with Norman Volsky🎙️ 🏥 📉! In just 9 minutes, we dig into: 💊 Why niche PBMs are gaining traction 🧬 How pharmacogenomics can drive better outcomes 🚀 What’s next in pharmacy benefits My take: precision medicine isn’t the future — it’s already here, and it’s creating real opportunities to improve care and reduce costs. If you manage pharmacy benefits, this is worth a quick listen ⤵

Drug costs keep rising and pharmacy strategy must keep up.     In our latest Healing Healthcare webisode, we spotlight how Blue Shield of California’s pharmacy transformation is creating more affordable and transparently priced prescription options for their members.     Our guest, Kathy Chang, PharmD, Head of Trade Relations at Blue Shield of California, shares how her team is:  • Increasing price transparency for members  • Delivering real-time drug pricing visibility  • Decentralizing the vendor model to remove waste  • Analyzing real-world medication performance to drive smarter decisions  • And more     Watch the full webisode here: https://lnkd.in/gDJ5SFTi

Sharing this important perspective from Archbow on how patient support programs must evolve to meet today’s engagement and outcomes expectations. This is an area where thoughtful strategy really makes a meaningful difference for patients and providers. #PatientSupport #Pharma #AccessStrategy #Engagement #ArchbowConsulting